All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Legend Biotech, Pfizer, and Roche. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
EHA2026 | Top abstracts: What’s hot in multiple myeloma and other plasma cell dyscrasias
To help navigate the exciting content being presented at the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.
| Oral presentations: Friday, June 12 | |||
| Abstract | Title | Presenter | Time (CEST) |
| S205 | Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study | Cyrille Touzeau | 17:15–17:30 |
| S207 | Aggressive smoldering curative approach evaluating novel therapies (ASCENT): A phase 2 trial of induction, consolidation, and maintenance in high-risk smoldering multiple myeloma | Shaji Kumar | 17:45–18:00 |
| S208 | Initial efficacy and safety data from the phase 1/2 LINKER-AL2 study of linvoseltamab (Linvo) monotherapy in patients with relapsed or refractory (RR) systemic light chain (AL) amyloidosis | Ashutosh Wechalekar | 18:00–18:15 |
| Oral presentations: Saturday, June 13 | |||
| Abstract | Title | Presenter | Time (CEST) |
| S100 | Phase 3, randomized study of talquetamab (Tal) plus daratumumab (Dara) ± pomalidomide (Pom) vs Dara plus Pom and dexamethasone (DPd) in relapsed/refractory multiple myeloma (RRMM): MonumenTAL-3 | Peter Voorhees | 12:15–12:30 |
| S195 | MAJESTEC-9: A phase 3 study of teclistamab monotherapy vs pomalidomide/bortezomib/dexamethasone or carfilzomib/dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM) | Cyrille Touzeau | 17:15–17:30 |
| S196 | Daratumumab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: Final analysis of transplant-ineligible patients in the phase 3 CEPHEUS study | Saad Z. Usmani | 17:30–17:45 |
| S198 | Teclistamab plus daratumumab (Tec-Dara) in patients (pts) with relapsed refractory multiple myeloma (RRMM): Analysis of MajesTEC-3 based on cytogenetic and functional risk | Rahul Banerjee | 18:00–18:15 |
| S199 | Safety and efficacy of iberdomide-based quadruplet for patients with newly diagnosed multiple myeloma: The IDEAL phase I/II trial results | Prashant Kapoor | 18:15–18:30 |
| Oral presentations: Sunday, June 14 | |||
| Abstract | Title | Presenter | Time (CEST) |
| LB5004 | Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial | Meletios Dimopoulos | 10:00–10:15 |
| Posters | |||
| Abstract | Title | Presenter | Date and time (CEST) |
| PF762 | DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM) | Enrique M. Ocio | Friday, June 12, from 18:45 |
| PF787 | Whole genome sequencing of multiple myeloma cells with a novel clinical assay uncovers diversity of genetic alterations underlying immunotherapy resistance | Bruno Paiva | Friday, June 12, from 18:45 |
| PF766 | Isatuximab–Rd induction followed by Isa‑R maintenance compared to Rd induction followed by R maintenance in elderly pts with NDMM with emphasis on frail and non-frail pts (AGMT MM04 trial) | Heinz Ludwig | Friday, June 12, from 18:45 |
| PS1862 | Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Updated 4-year results of the phase 3 DREAMM-7 trial | Vania Hungria | Saturday, June 13, from 18:45 |
| PS1865 | Cevostamab (FcRH5xCD3 bispecific antibody) induces durable responses in patients with late-line RRMM who have received prior BCMA-targeted CAR T-cell therapy: Expansion results from the CAMMA 2 study | Shaji Kumar | Saturday, June 13, from 18:45 |
| PS1875 | Iberdomide plus daratumumab and dexamethasone in newly diagnosed multiple myeloma (NDMM) by renal function: Subgroup analysis of the CC-220-MM-001 trial | Anna Sureda | Saturday, June 13, from 18:45 |
| PS1877 | Belantamab mafodotin, pomalidomide, and dexamethasone (BPd) demonstrated improved outcomes as second-line therapy vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients with multiple myeloma | Meral Beksaç | Saturday, June 13, from 18:45 |
| PS1882 | Establishing fully outpatient ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: First clinical data from Europe | Tim Richardson | Saturday, June 13, from 18:45 |
| PS1896 | Elranatamab in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-20 trial | C. Ola Landgren | Saturday, June 13, from 18:45 |
| PS1919 | Outpatient step-up dosing of teclistamab or talquetamab with prophylactic tocilizumab in patients with relapsed/refractory multiple myeloma: Real-world evidence from a large US cancer center | Cesar Rodriguez | Saturday, June 13, from 18:45 |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
